Eli Lilly and Company
LLY · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $684 | $700 | $742 | $693 |
| - Cash | $10 | $3 | $3 | $3 |
| + Debt | $43 | $40 | $39 | $34 |
| Enterprise Value | $717 | $736 | $777 | $723 |
| Revenue | $18 | $16 | $13 | $14 |
| % Growth | 13.1% | 22.2% | -5.9% | – |
| Gross Profit | $15 | $13 | $11 | $11 |
| % Margin | 82.9% | 84.3% | 82.5% | 82.2% |
| EBITDA | $8 | $8 | $4 | $6 |
| % Margin | 44.8% | 48.2% | 32.7% | 42.5% |
| Net Income | $6 | $6 | $3 | $4 |
| % Margin | 31.7% | 36.4% | 21.7% | 32.6% |
| EPS Diluted | 6.21 | 6.29 | 3.06 | 4.88 |
| % Growth | -1.3% | 105.6% | -37.3% | – |
| Operating Cash Flow | $9 | $3 | $2 | $2 |
| Capital Expenditures | -$0 | -$2 | -$3 | -$2 |
| Free Cash Flow | $9 | $1 | -$2 | $1 |